TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20980493
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg folic acid/d
Study: 11359167
Drug: Vitamins C
Normalized name: MULTIVITAMINS CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamins C and E (1 g ascorbic acid and 600 IU d-alpha-tocopherol daily before diving)
Study: 9236432
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 mg/d PO for up to 36 days)
Study: 8179973
Drug: Cisapride (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (10 mg four times a day)
Study: 21429809
Drug: Subcutaneous methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous methylnaltrexone 12 mg once daily (QD)
Study: 21429809
Drug: Subcutaneous methylnaltrexone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous methylnaltrexone 12 mg every other day (alternate-day dosing)
Study: 12687868
Drug: Cardioverter defibrillator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioverter defibrillator shock therapy
Study: 8823558
Drug: Itraconazole 100
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100 mg once daily for six weeks
Study: 8823558
Drug: Itraconazole 50
Normalized name: ITRACONAZOLE 50MG/5ML SOLN,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 50 mg once daily for six weeks
Study: 1315661
Drug: Deferral of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferral of treatment
Study: 29924010
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy (n = 30)
Study: 29924010
Drug: Bath therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bath therapy (n = 30)
Study: 27129125
Drug: Tofacitinib 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 30 mg twice daily
Study: 27138968
Drug: Microgynon 30®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgynon 30® tablet (30 μg EE and 150 μg LN)
Study: 24502751
Drug: Ecological momentary
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ecological momentary assessment using the Daytime Insomnia Symptom Scale (DISS) administered 4 times daily for 7 days.
Study: 15018324
Drug: Single intracisternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intracisternal injection of recombinant tPA (400 microg/ml, 500 microg/ml, 700 microg/ml, 800 microg/ml in 20 ml distilled water at pH 7)
Study: 15018324
Drug: Single intracisternal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intracisternal injection of recombinant tPA
Study: 10771973
Drug: Inhaled dexamethasone
Normalized name: dexamethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled dexamethasone
Study: 30017261
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) responders and remitters
Study: 26931279
Drug: Teriparatide (TPTD)
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide (TPTD) 20 μg/d (subcutaneous injection)
Study: 26931279
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic Acid (ZOL) 5 mg/yr (intravenous infusion)
Study: 24852357
Drug: Previously received
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previously received mental health treatment
Study: 20391044
Drug: Cyanocobalamin nasal
Normalized name: cyanocobalamin nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyanocobalamin nasal spray for 8 weeks
Study: 12094192
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with ST-segment resolution at 90 minutes
Study: 12094192
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with ST-segment resolution at 180 minutes
Study: 8948272
Drug: Alendronate 20/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 20/5 mg
Study: 7484285
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg
Study: 1682685
Drug: Capsaicin (NANC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin (NANC stimulant)
Study: 29921404
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of contraceptive pill + local treatment + pulsed‐vacuum light (Group I)
Study: 29921404
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment only (Group III)
Study: 29921404
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of contraceptives + pulsed‐vacuum light (Group II)
Study: 25057173
Drug: Vandetanib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib (100 mg/day) plus docetaxel (75 mg/m(2) every 21 days)
Study: 22173910
Drug: Cocoa-liquor-free control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa-liquor-free control chocolate (CC)
Study: 17205032
Drug: Erythromycin 200
Normalized name: ERYTHROMYCIN 200 mg in 2 g TOPICAL POWDER [API E.M. Erythromycin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 200 mg intravenously twice a day
Study: 17205032
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg intravenously four times daily
Study: 17205032
Drug: Rescue combination
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue combination therapy (open-label)
Study: 12509907
Drug: Tinnitus retraining
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinnitus retraining therapy (TRT) with drugs
Study: 12509907
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with tinnitus masking and drugs
Study: 7644082
Drug: Oral sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sumatriptan 25 mg, 50 mg, or 100 mg
Study: 952109
Drug: Combined polychemotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined polychemotherapy with high doses of cytostatics applied intermittently after radical surgery.
Study: 28866675
Drug: Ranibizumab 0.5
Normalized name: RANIBIZUMAB 0.5MG/0.05ML INJ,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (2 intravitreal loading doses at 4-week intervals)
Study: 23744759
Drug: HPβCD-diclofenac (IV)
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPβCD-diclofenac (IV) 18.75 mg
Study: 23744759
Drug: HPβCD-diclofenac (IV)
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPβCD-diclofenac (IV) 37.5 mg
Study: 23744759
Drug: Cataflam 50
Normalized name: Cataflam 50mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cataflam 50 mg (oral)
Study: 17147046
Drug: Sodium enoxaparin
Normalized name: Enoxaparin Sodium
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium enoxaparin administered subcutaneously at a dose of 4,000 IU once a day for 10 days, combined with venovenous hemofiltration performed at the first and last day of the protocol
Study: 17147046
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (cortisone, vasoactive agents, and vitamin complexes) administered in physiological solution intravenously twice daily for 10 days
Study: 10840422
Drug: Monthly BCG
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly BCG
Study: 10840422
Drug: Alternating monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Alternating monthly interferon-alpha and BCG
Study: 2085986
Drug: Norfloxacin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin (800 mg)
Study: 3107462
Drug: Thiamphenicol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamphenicol (2.5 g)
Study: 20002719
Drug: Paracetamol 15
Normalized name: Paracetamol 150 mg and sodium salicylate 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 15 mg/kg/dose every 4 h
Study: 20002719
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg/kg/dose every 8 h
Study: 20002719
Drug: Paracetamol and
Normalized name: Paracetamol and tramadol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol and Ibuprofen (both groups)
Study: 12765607
Drug: Antibodies against
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies against beta-amyloid (aggregated Abeta(42))
Study: 6145426
Drug: fluperlapine 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluperlapine 5 mg
Study: 6145426
Drug: fluperlapine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluperlapine 10 mg
Study: 6145426
Drug: clozapine 5
Normalized name: clozapine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clozapine 5 mg
Study: 6145426
Drug: clozapine 10
Normalized name: clozapine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: clozapine 10 mg
Study: 3527402
Drug: Chlorambucil (CB)
Normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorambucil (CB) and Prednisone (P) for induction therapy
Study: 25795406
Drug: Trabectedin (1·2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin (1·2 mg/m² via central venous line over 24 h on day 1 of a 21 day treatment cycle)
Study: 23940307
Drug: Spironolactone (titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (titrated to 25 or 50 mg daily)
Study: 20886786
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Duphalac)
Study: 14555263
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate (2 mg every 3 months) and calcium (1000 mg daily)
Study: 14555263
Drug: Intravenous ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ibandronate (2 mg every 3 months) and calcium (1000 mg daily) with 700 IU vitamin D daily in the second year
Study: 11078987
Drug: Urinary iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Urinary iodine concentration (UIC) measured in microg/l
Study: 1316330
Drug: Fluoxetine 60
Normalized name: fluoxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 60 mg daily for 14 days
Study: 2579953
Drug: Dextran 40
Normalized name: Dextran 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 40 peroperatively plus 0.5 g aspirin a day for 10 days
Study: 2579953
Drug: Heparin calcium
Normalized name: HEPARIN CALCIUM
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heparin calcium 5000 iu subcutaneously plus dihydroergotamine (DHE) 0.5 mg intramuscularly for 10 days
Study: 2579953
Drug: Dextran/aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran/aspirin
Study: 2579953
Drug: DHE/heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHE/heparin
Study: 31895884
Drug: Lifitegrast ophthalmic
Normalized name: lifitegrast ophthalmic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifitegrast ophthalmic solution 5% twice daily for 42 days
Study: 30396189
Drug: Oral Health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Health Program (OHP)
Study: 24958410
Drug: Integrated cardiopulmonary
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated cardiopulmonary sonography with standard treatment
Study: 25417402
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment only (Control)
Study: 10831103
Drug: 228-ppm-F two-solution
Normalized name: POUCH,OSTOMY TWO PIECE SYSTEM F#145-0519
Approvals — FDA: no, EMA: no, PMDA: no
Description: 228-ppm-F two-solution rinse
Study: 8795596
Drug: Amantadine hydrochloride
Normalized name: Amantadine Hydrochloride
DrugBank: Amantadine (DB00915)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amantadine hydrochloride (AH; 200 mg daily)
Study: 1321248
Drug: Lisinopril (5‐40mg/day,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (5‐40mg/day, mean dose 11 mg/day)
Study: 1321248
Drug: Low-dose trichlormethiazide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose trichlormethiazide (2.0‐4.0 mg/day, mean dose 2.2 mg/day)
Study: 1321248
Drug: Lisinopril and
Normalized name: lisinopril and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril and low-dose trichlormethiazide
Study: 6427483
Drug: Long-term mitomycin
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term mitomycin C instillation therapy
Study: 24251381
Drug: Deferiprone (DFP)
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Deferiprone (DFP) 30 mg/kg/day
Study: 22105798
Drug: Carbomer gel
DrugBank: Carbomer (DB15649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbomer gel
Study: 17703832
Drug: Intravenous epoetin-delta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin-delta (ED)
Study: 11549300
Drug: Modified release
Normalized name: MODIFIED RELEASE CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified release dipyridamole (200 mg b.i.d. p.o.)
Study: 9476765
Drug: Fibrin glue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin glue (FG) injections
Study: 9476765
Drug: Hypertonic saline-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline-epinephrine (HSE) injections
Study: 7946231
Drug: Open-door rehabilitation
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-door rehabilitation treatment
Study: 7946231
Drug: Standard locked-ward
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard locked-ward treatment
Study: 29912782
Drug: Cardiac shock-wave
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac shock-wave therapy (CSWT) in addition to optimal medical treatment (OMT)
Study: 29912782
Drug: Optimal medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal medical therapy with sham procedure (OMT+placebo)
Study: 28938905
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg with sustained-release (SR) sarpogrelate 300 mg (Anplone®) once a day for six months
Study: 28938905
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg with clopidogrel 75 mg once a day for six months
Study: 24687169
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride (500 mg) twice daily for 4 months
Study: 24687169
Drug: Placebo twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice daily for 4 months
Study: 22851564
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg twice a day) plus gemcitabine (1,250 mg/m² on days 1 and 8) and cisplatin (75 mg/m² on day 1)
Study: 22851564
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus gemcitabine (1,250 mg/m² on days 1 and 8) and cisplatin (75 mg/m² on day 1)
Study: 22851564
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg twice a day)
Study: 17296390
Drug: Verapamil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (10 mg in 4 cc saline) via electromotive drug administration
Study: 17296390
Drug: Saline (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (4 cc) via electromotive drug administration
Study: 9732153
Drug: 3-day oral
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-day oral itraconazole (200 mg daily)
Study: 9732153
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral fluconazole (150 mg)
Study: 9732153
Drug: 6-day intravaginal
Normalized name: taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-day intravaginal clotrimazole (100 mg daily)
Study: 12283426
Drug: gemeprost 1
Normalized name: Gemeprost 1 mg vaginal pessary
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemeprost 1 mg pessaries
Study: 12283426
Drug: PGE2 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PGE2 7.5 mg gel
Study: 6244920
Drug: Captopril (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (150 mg t.i.c.)
Study: 6244920
Drug: Captopril (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (150 mg t.i.c.) + Hydrochlorothiazide
Study: 17425493
Drug: Current therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current therapies
Study: 30389229
Drug: CoQ10 supplementation
Normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CoQ10 supplementation (400 mg/d)
Study: 28143495
Drug: Structured SMBG
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured SMBG with additional monthly telecare support from a trained study nurse
Study: 25929840
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care intervention package for depression (psychoeducation, activity scheduling, problem solving treatment, and medication for severe depression)
Study: 17109282
Drug: Intraventricular rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular rt‐PA treatment
Study: 7996391
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of (+)-sotalol 50, 100, 200, and 300 mg
Study: 7996391
Drug: Repeated oral
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated oral doses of (+)-sotalol 200 mg twice daily for 6.5 days
Study: 7996391
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous doses of (+)-sotalol 1.0 and 1.5 mg kg-1
Study: 3069682
Drug: Acebutolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (200 mg twice a day)
Study: 18606983
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg orally once daily on days 1 to 21, every 28 days, for 52 weeks
Study: 18606983
Drug: Lenalidomide 25
Normalized name: lenalidomide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide 25 mg orally
Study: 3354029
Drug: Nimodipine 240
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 240 mg/day
Study: 3354029
Drug: Nimodipine 120
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine 120 mg/day
Study: 31211416
Drug: 200 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 μg of oral vitamin K2
Study: 31211416
Drug: 400 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 μg of oral vitamin K2
Study: 31211416
Drug: Both vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vitamin K2 arms (200 μg and 400 μg)
Study: 22684211
Drug: Lumbar extension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar extension traction in addition to hot packs and interferential therapy
Study: 22684211
Drug: Hot packs
Normalized name: Red Hot
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hot packs and interferential therapy
Study: 16527405
Drug: 30% l‐menthol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% l‐menthol in ethanol
Study: 14504920
Drug: Irinotecan 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 350 mg/m2 every 21 days (Group A)
Study: 14504920
Drug: Irinotecan 175
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 175 mg/m2 days 1 and 10 every 21 days (Group B)
Study: 12545845
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) treatment at a dose of 0.5 IU/(kg d) subcutaneously between days 3‐17 post‐burn
Study: 3912616
Drug: Chemotherapy +
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy + tamoxifen (Group CH)
Study: 3912616
Drug: Chemotherapy only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy only (Group C)
Study: 25047263
Drug: Fluorotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorotherapy with sodium fluoride (Elmex fluoride gel® 1.25%) administered once daily for 1 year
Study: 19674252
Drug: Endothelial antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelial antioxidant compounds (EAC) plus sildenafil (100 mg)
Study: 19674252
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg) alone
Study: 17652885
Drug: Intensive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid-lowering therapy (target LDL-C <70 mg/dl)
Study: 17652885
Drug: Moderate lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate lipid-lowering therapy (target LDL-C <100 mg/dl)
Study: 7772628
Drug: ranitidine 100
Normalized name: ranitidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 100 mg twice daily intravenously from the day before operation until the third postoperative day
Study: 7465140
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g cefamandole
Study: 26277254
Drug: Physiotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy treatment alone (control group)
Study: 21604490
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg lansoprazole IV infusion
Study: 21604490
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg lansoprazole IV infusion
Study: 21604490
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg lansoprazole IV infusion